scholarly journals Changes in Serum Fatty Acids and Inflammatory Markers in Postmenopausal Women With Breast Cancer Following Chemotherapy Treatment

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 290-290
Author(s):  
Zihan Zhang ◽  
Kate Ormiston ◽  
Patrick Schnell ◽  
Rachel Kopec ◽  
Maryam Lustberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fatty Acids ◽  
Inflammatory Markers ◽  
Postmenopausal Breast Cancer ◽  
Cancer Center ◽  
Future Research ◽  
Total N ◽  
Serum Cytokines ◽  
Significant Difference ◽  
Serum Fatty Acids

Abstract Objectives Chemotherapy induces an inflammatory state. Fatty acids (FAs) are potent signaling molecules that can alter inflammation. The objective of this research was to examine if serum fatty acids and inflammatory markers in postmenopausal breast cancer patients changed during and after chemotherapy. Methods Serum samples from 60 women undergoing chemotherapy for breast cancer were collected at baseline (n = 50), the fourth cycle of chemotherapy (chemo-4; n = 40), and 6 months after chemotherapy (6M post-chemo; n = 34). Serum F As were extracted, methylated, then analyzed using gas chromatography; serum cytokines were analyzed using multiplex enzyme-linked immunoassay. After natural log-transformation data were analyzed by one-way analysis of variance (ANOVA) followed by post hoc tests using Tukey's Honest Significant Difference test. Results From baseline to chemo-4, C18:0, C20:0, and C22:5n6 significantly decreased (P < 0.05 for all) while C18:1n9, total n-9 FAs, total monounsaturated FAs (MUFAs), and tumor necrosis factor alpha-receptor II (TNF-RII) increased (P < 0.05 for all). From chemo-4 to 6M post-chemo, FAs did not change significantly; however, interleukin-6 (IL-6) and IL-8 increased (P < 0.05). From baseline to 6M post-chemo, C20:0 significantly decreased (P < 0.05) while C18:1n9, C20:1n9, total n-9 FAs, total MUFAs significantly increased (P < 0.05 for all); additionally, the n-3/n-6 ratio and IL-6 significantly increased (P < 0.05 for all). Conclusions There were significant changes in serum FAs and serum cytokines in women with breast cancer undergoing chemotherapy. Cytokine changes were consistent with a more inflammatory profile during and after chemotherapy. Future research will investigate associations between serum FAs and serum inflammatory markers in breast cancer survivors undergoing chemotherapy. Funding Sources The Ohio State University Stefanie Spielman Breast Cancer Center Kroger Fund.

scholarly journals Associations of Long Chain Polyunsaturated Fatty Acid Biomarkers with Affective Symptoms and Cognition in Women Beginning Chemotherapy for Breast Cancer

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 366-366
Author(s):  
Zihan Zhang ◽  
Kate Ormiston ◽  
Tonya Orchard ◽  
Maryam Lustberg ◽  
Patrick Schnell
Keyword(s):  
Breast Cancer ◽  
Fatty Acids ◽  
Executive Function ◽  
Comprehensive Cancer Center ◽  
Chain Polyunsaturated Fatty Acid ◽  
Cancer Center ◽  
Total N ◽  
Loneliness Scale ◽  
Affective Symptoms ◽  
Long Chain

Abstract Objectives The objective of this research was to examine if the serum levels of long chain omega 3 fatty acids (LCn-3 FA) or long chain omega-6 fatty acids (LCn-6 FA) were associated with affective symptoms and cognition in breast cancer patients beginning chemotherapy. Methods 60 women with breast cancer were assigned to a double-blinded randomized study of minocycline vs placebo. Serum was collected from 53 women at baseline and post-chemotherapy and was stored at −80C. Serum fatty acids (FAs) from 37 pairs of samples from both time points were extracted, methylated, then analyzed using gas chromatography. Changes in fatty acids were analyzed by using paired sample t-test. Cognitive and affective behaviors were measured by Behavior Rating Inventory of Executive Function—Adult Version (BRIEF-A) test, The State-Trait Anxiety Inventory (STAI), and UCLA 3 item Loneliness Scale. Associations between baseline FAs and cognitive and affective test scores were measured by Pearson correlations; p < 0.05 was considered significant. Results Preliminary results suggest there were significant increases in the following serum FAs from baseline to post chemotherapy: C14:0 (p < 0.05) and C18:1n9 (p < 0.05), and there were significant decreases in C18:0 (p = 0.01), C20:0 (p = 0.001), and C22:5n6 (p < 0.05). Baseline analysis, prior to chemotherapy, indicated a non-significant trend for EPA (20:5n3) (r = −0.27, p = 0.06) and the n-3/n-6 ratio (r = −0.27, p = 0.06) to be correlated with better (i.e., lower) scores on the BRIEF-A test. There were trends for correlations of total n-6 FA and better (i.e., lower) STAI score (r = −0.25, p = 0.07), and total n-6 FA and better (i.e., lower) Loneliness Scale scores (r = −0.24, p = 0.09). Conclusions There was a significant change in the serum FA profile of women with breast cancer from baseline to post-chemotherapy. There were non-significant trends for n-3 FAs to be associated with better executive function, and n-6 FAs to be correlated with less anxiety and loneliness prior to beginning chemotherapy. Future research will investigate associations among serum FAs, cognitive and affective tests post-chemotherapy. Funding Sources Stephanie Spielman Breast Cancer Center – Kroger Fund OSU Comprehensive Cancer Center Pelotonia Award.

Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e13056-e13056
Author(s):  
Michael Grimm ◽  
Bhuvaneswari Ramaswamy ◽  
Maryam B. Lustberg ◽  
Robert Wesolowski ◽  
Sagar D. Sardesai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Metastatic Breast ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Her2 Status ◽  
Single Institution ◽  
First Line ◽  
Response To Chemotherapy ◽  
Significant Difference

e13056 Background: Invasive lobular carcinoma (ILC) accounts for only 10-15% of all invasive breast cancers but has distinct clinicopathologic characteristics and genomic profiles. In particular, metastatic lobular cancers (mILC) have unique sites of metastasis and it is unclear if the response to initial endocrine therapy differs from metastatic ductal cancers (mIDC). Therefore we have undertaken a single-institution, retrospective analysis to compare overall outcomes and response to initial endocrine therapy (ET) in patients (pts) with metastatic ILC and IDC. Methods: An IRB approved retrospective review of medical records was conducted evaluating pts treated for metastatic IDC and ILC at The Ohio State University Comprehensive Cancer Center from January 1, 2004 to December 31, 2014. Pts diagnosed with mIDC were matched on age, year of diagnosis, estrogen receptor/progesterone receptor and HER2 status and site of metastasis 2:1 to patients diagnosed with mILC. Overall survival (OS) was defined as the time from metastasis to death or last known follow-up. Progression-free survival (PFS) was defined as time from metastasis to progression on first-line ET. Time to chemotherapy (TTC) was defined as time from starting ET for metastasis to initiation of chemotherapy. Kaplan Meier (KM) methods were used to calculate median OS, PFS and TTC. Results: A total of one hundred sixty one pts with metastatic breast cancer were included in this analysis. The demographic features between the two groups were well balanced and included in the table below. The median OS was 2.6 yrs (95% CI: 1.55, 3.22) for mILC and 2.2 yrs (95% CI: 1.95, 2.62) for mIDC. A subset of 111 patients who started on endocrine therapy were used in the PFS and TTC analyses. The median PFS following first-line ET was 2.2 yrs (95% CI: 0.1.0, 2.7) for mILC and 1.4 yrs (95% CI: 0.91, 1.90) for mIDC. Median TTC was 2.1 yrs (95% CI: 1.71, 4.92) for mILC and 2.4 yrs (95% CI: 1.90, 4.77) for mIDC. There was no statistically significant difference in outcomes between the two groups. Conclusions: Outcomes in patients with ILC and IDC have been varied, with several studies reporting that patients with ILC have worse outcomes and response to chemotherapy. Our retrospective study examining outcomes in mILC in comparison with mIDC showed no difference in OS. Given the concern of resistance to conventional therapies in patients with lobular cancers, it is reassuring to see that the median PFS on first line ET and TTC was similar to metastatic ductal cancers.[Table: see text]

scholarly journals Role of n-3 Polyunsaturated Fatty Acids and Exercise in Breast Cancer Prevention: Identifying Common Targets

2016 ◽  
Vol 9 ◽  
pp. NMI.S39043 ◽  
Author(s):  
Salma A. Abdelmagid ◽  
Jessica L. MacKinnon ◽  
Sarah M. Janssen ◽  
David W.L. Ma
Keyword(s):  
Breast Cancer ◽  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Cancer Prevention ◽  
Breast Cancer Prevention ◽  
Future Research ◽  
Pufa Intake ◽  
Diet And Exercise ◽  
Important Study

Diet and exercise are recognized as important lifestyle factors that significantly influence breast cancer risk. In particular, dietary n-3 polyunsaturated fatty acids (PUFAs) have been shown to play an important role in breast cancer prevention. Growing evidence also demonstrates a role for exercise in cancer and chronic disease prevention. However, the potential synergistic effect of n-3 PUFA intake and exercise is yet to be determined. This review explores targets for breast cancer prevention that are common between n-3 PUFA intake and exercise and that may be important study outcomes for future research investigating the combined effect of n-3 PUFA intake and exercise. These lines of evidence highlight potential new avenues for research and strategies for breast cancer prevention.

Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11020-e11020 ◽  
Author(s):  
Ugur Sahin ◽  
Ibrahim Petekkaya ◽  
Cagatay Arslan ◽  
Saim Furkan Sarici ◽  
Mustafa Solak ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitors ◽  
Adjuvant Treatment ◽  
Hormone Receptor ◽  
Postmenopausal Breast Cancer ◽  
Type I ◽  
Obese Patients ◽  
Hormone Receptor Positive ◽  
Significant Difference

e11020 Background: Aromatase inhibitors (AIs), anastrozole (ANA) and letrozole (LET), have been shown to be more effective than tamoxifen in the adjuvant treatment of postmenopausal hormone receptor positive breast cancer. However, data from preclinical studies and subgroup analyses of some major clinical trials suggest differring efficacy among AIs. Yet the best clinical choice is still not very clear. This retrospective study aims at comparing the results of treatment with either AI among different subgroups of patients, especially among the obese patients. Methods: Between 2006-2011, 335 women with stage I to IIIC hormone receptor positive postmenopausal breast cancer treated with either ANA or LET as adjuvant treatment were included. Body mass index (BMI), estrogen and progesterone receptor (ER and PR) and HER-2 status at the time of diagnosis were recorded. Patients were grouped as BMI ≤ 30 and BMI > 30. The Kaplan-Meier survival estimates were calculated. Subgroups were compared with the log rank test. A 5 % type-I error was used to infer statistical significance. Results: The percentage of patients receiving ANA or LET were 47.2% and 57.8%, respectively. Median age at diagnosis was 58 (42-84) and lower in the ANA group (p=0.04). Stage II to IIIC disease was present in 76.8 % and the distribution was similar between ANA and LET (p=0.84). Median time of follow-up was 29 months (6-124) and median duration of hormonotherapy was 29 months (3-68) and similar between two groups (p=0.52 and p=0.55, respectively). Of the patients 41.2 % had a BMI of > 30. There was no significant difference in overall (OS) and progression-free (PFS) survivals between ANA and LET (p=0.08 and p=0.94, respectively). However, among patients with a BMI of > 30 a statistically insignificant benefit in PFS was observed with LET (p=0.1). ER, PR and HER2 status had no significant impact on OS and PFS. Conclusions: In a median follow-up of 29 months letrozole and anastrozole yielded similar OS and PFS. However, among patients with a BMI of > 30, LET might bring about a PFS advantage. In selected obese patients LET might be a reasonable choice in this setting. Larger studies with long term follow-up are needed to reach an exact conclusion.

scholarly journals Radiotherapy improves serum fatty acids and lipid profile in breast cancer

2017 ◽  
Vol 16 (1) ◽  
Author(s):  
Sana Shaikh ◽  
Naseem Aslam Channa ◽  
Farha Naz Talpur ◽  
Muhammad Younis ◽  
Naila Tabassum
Keyword(s):  
Breast Cancer ◽  
Fatty Acids ◽  
Lipid Profile ◽  
Serum Fatty Acids

scholarly journals Evaluation of Pentosidine as Bone Quality Marker in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors

2020 ◽  
Author(s):  
Hideo Shigematsu ◽  
Tomoyuki Yoshiyama ◽  
Daisuke Yasui ◽  
Shinji Ozaki
Keyword(s):  
Breast Cancer ◽  
Bone Turnover ◽  
Cancer Patients ◽  
Bone Quality ◽  
Bone Turnover Markers ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Average Change ◽  
Turnover Markers

Abstract Background: Osteoporosis and fractures are important aromatase inhibitor (AI) related adverse events in postmenopausal women with hormone receptor positive breast cancer. An increment of pentosidine is associated with a deterioration of bone quality. In this study, pentosidine was evaluated in postmenopausal breast cancer patients receiving AIs. Methods: Fifty postmenopausal breast cancer patients receiving AIs were retrospectively evaluated. Sixteen patients were given a bone modifying agent (BMA) concomitant with AIs. Changes of pentosidine, bone turnover markers and bone mineral density (BMD) before and after 12 months of AI therapy were compared between BMA administered patients (BMA group) and a non-BMA group.Results: There was no significant difference between pentosidine low and high groups in regard to age, height, weight, BMD of femoral neck and lumbar spine, and bone turnover markers including TRACP-5b and BAP. In the non-BMA group, pentosidine was increased in 18 cases (53%), and the average change of pentosidine was 21.5% (95%CI; 0.23 to 42.7%, p=0.048). In the BMA group, pentosidine was increased in 2 two cases (13%), and the average change of pentosidine was -16.6% (95%CI; -30.6 to -2.6%, p=0.023). There was a significantly lower proportion of pentosidine-increased cases (p=0.0065) and decrease of pentosidine (p=0.021) in the BMA group compared to those in the non-BMA group. Conclusions: Pentosidine was an independent factor from risk factors of osteoporotic fracture. Pentosidine was increased with AI, however, BMA inhibits an AI-induced increase of pentosidine in postmenopausal breast cancer patients.

scholarly journals Tualang Honey Supplementation Improves Inflammatory and Bone Markers among Postmenopausal Breast Cancer Patients: A Randomised Controlled Trial

2021 ◽  
Vol 50 (7) ◽  
pp. 1971-1985
Author(s):  
Zaida Zakaria ◽  
Wan Zuraida Wan Ab Hamid ◽  
Mahaneem Mohamed
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Inflammatory Markers ◽  
Bone Markers ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Post Intervention ◽  
Amino Terminal ◽  
Tualang Honey

Honey is traditionally used among breast cancer patients in Malaysia with the belief that it can improve the overall health. Therefore, this study aims to determine the effects of Tualang honey supplementation on levels of inflammatory markers, bone markers and oestradiol among postmenopausal breast cancer patients. Seventy-two patients on anastrozole were recruited and randomly divided into two groups (n = 36/group, with or without 20 g/day of Tualang honey for 12 weeks). Levels of interleukin-1 beta (IL-1β), tumour necrosis factor alpha (TNF-α) and carboxy-terminal crosslinked telopeptide of type 1 collagen (CTX) at post-intervention with anastrozole, increased significantly compared to their corresponding levels at pre-intervention. Meanwhile, at post-intervention with anastrozole+honey, procollagen type 1 amino-terminal propeptide level increased significantly, CTX level decreased significantly, with no change in inflammatory markers compared to their pre-intervention levels. In conclusion, Tualang honey supplementation prevented the increased inflammation, reduced bone resorption and increased bone formation without changes in oestradiol level.

Sign in / Sign up

Export Citation Format

Share Document